2025 Q3 -tulosraportti
59 päivää sitten36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
250
Myynti
Määrä
5 860
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 250 | AVA | NON | ||
| 500 | NON | NON | ||
| 640 | NON | NON | ||
| 782 | NON | NON | ||
| 224 | AVA | NON |
Ylin
12,65VWAP
Alin
11,85VaihtoMäärä
1 80 131
VWAP
Ylin
12,65Alin
11,85VaihtoMäärä
1 80 131
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sitten · MuokattuTechnical Analysis Curasight is in a rising trend channel in the medium term. Rising trends indicate that the company is in a positive development, and that buying interest among investors is increasing. There is no resistance in the price chart, and a further upturn is indicated. In case of reactions back, the stock has support at approximately 6.40 kronor. https://www.investtech.com/dk/market.php?CompanyID=46110272
·1 päivä sittenYet another site where Curasight's name has popped up. Published 4 hours ago: https://www.towardshealthcare.com/companies/brain-cancer-companies Towardshealthcare describes themselves as: "We are a global strategy consulting firm based in Canada and India, dedicated to helping business leaders gain a competitive edge and accelerate growth. As a trusted provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, we are committed to building creative partnerships that generate actionable insights and drive meaningful innovation."
·1 päivä sittenSales order for 51,022 units at 12.60 kr 🥲- ·1 päivä sittenCurasight is mentioned in this LinkedIn post: Radioimmunotherapy Market Overview: Significant Growth Potential with 14.5% CAGR Forecast from 2026 to 2033 https://www.linkedin.com/pulse/radioimmunotherapy-market-overview-significant-growth-potential-q0jhf?utm_source=share&utm_medium=member_android&utm_campaign=share_via
·2 päivää sittenThanks for the input, SweetSpot. Good observations. I agree that silence should probably be expected - but for once, it can advantageously be regarded as positive silence. Conversely, I would become skeptical if a company were to adorn itself with a lot of feathers right now; then one would almost instinctively know that JPM had not been a success. Silence right now must, all things considered, mean that one is quietly working through the current processes and everything is proceeding calmly in the background. No reason to shout out loud unless something "must" be announced. They have given people all autumn and winter to position themselves, now it's just a matter of being patient.
·2 päivää sitten · MuokattuThanks. Completely agree that the autumn was used by management to position Curasight and after a period of intensive news flow, Curasight has now entered a phase where silence in itself is information. It is precisely in this transition – from public validation to Big Pharma's internal decision-making maturation – that many investors experience uncertainty, because there are no longer frequent data points or other communication from the company. But where is Curasight really in the process, what does the capital preparedness mean and how should the communication be interpreted – what does the current silence actually signal – both to the market and to Big Pharma. --------------------------------------------------------- 1. Capital Preparedness – Fenja in correct context The Fenja loan agreement (potential dilution of approx. 2 million shares) should not be read as a sign of weakness, but as deliberate bridge financing. The agreement: • secures runway until expected milestone payments from Curium • eliminates short-term capital stress • strengthens Curasight's negotiating position A dilution of approx. 4–5 % is a low price for strategic freedom. For industrial players, the signal is clear: Curasight is not a forced seller. And a company without capital stress can afford to say no – and wait. ------------------------------------------------------- 2. What is Big Pharma doing now? Big Pharma is not passively awaiting. Under NDA, typically occurs: • ongoing receipt of updated clinical data • internal investment and portfolio discussions • ongoing updating of price and risk models • structure and timing considerations (option vs. acquisition) • competitor monitoring: “are there others in the room?” Waiting time is used for risk reduction and decision maturation – not stagnation. ---------------------------------------------------------- 3. Communication, silence and FBM Curasight is not obliged to communicate: • NDA dialogues • ongoing negotiations • potential strategic interest An FBM is only issued when a binding agreement exists. The classic sequence is: NDA → data sharing → terms → board approval → FBM Silence in this phase is therefore not an absence of activity, but standard and value-preserving practice. ----------------------------------------------------------- 4. Preparatory communication is key. The current communication is process-oriented, low-key, and legally balanced. It signals readiness without locking in structure, timing, or price. Preparatory communication is typically only used when: • the mechanistic risk is reduced • capital pressure is low • several strategic structures are possible • timing is strategically important This precisely matches Curasight's situation. ----------------------------------------------------------- Conclusion: The Curasight case is not finished – but it is finished being early. The case is now in a decision space where timing, structure, and competition mean more than the mechanism itself. This is mentally demanding, because it is precisely here that the greatest asymmetries arise – but analytically, the picture is consistent. In principle, the market could wake up to an FBM where: • the company has been sold to a Big Pharma company • or where an optioned partnership agreement has been entered into for the coming months in connection with further clinical development of uTREAT Both will in practice make the case more expensive for Big Pharma, because further clinical progress further reduces the risk. Everything currently points in a constructive direction. This does not change the fact that discipline is required – but at present, there is nothing that indicates structural weakness.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
59 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sitten · MuokattuTechnical Analysis Curasight is in a rising trend channel in the medium term. Rising trends indicate that the company is in a positive development, and that buying interest among investors is increasing. There is no resistance in the price chart, and a further upturn is indicated. In case of reactions back, the stock has support at approximately 6.40 kronor. https://www.investtech.com/dk/market.php?CompanyID=46110272
- ·1 päivä sittenYet another site where Curasight's name has popped up. Published 4 hours ago: https://www.towardshealthcare.com/companies/brain-cancer-companies Towardshealthcare describes themselves as: "We are a global strategy consulting firm based in Canada and India, dedicated to helping business leaders gain a competitive edge and accelerate growth. As a trusted provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, we are committed to building creative partnerships that generate actionable insights and drive meaningful innovation."
- ·1 päivä sittenSales order for 51,022 units at 12.60 kr 🥲
- ·1 päivä sittenCurasight is mentioned in this LinkedIn post: Radioimmunotherapy Market Overview: Significant Growth Potential with 14.5% CAGR Forecast from 2026 to 2033 https://www.linkedin.com/pulse/radioimmunotherapy-market-overview-significant-growth-potential-q0jhf?utm_source=share&utm_medium=member_android&utm_campaign=share_via
- ·2 päivää sittenThanks for the input, SweetSpot. Good observations. I agree that silence should probably be expected - but for once, it can advantageously be regarded as positive silence. Conversely, I would become skeptical if a company were to adorn itself with a lot of feathers right now; then one would almost instinctively know that JPM had not been a success. Silence right now must, all things considered, mean that one is quietly working through the current processes and everything is proceeding calmly in the background. No reason to shout out loud unless something "must" be announced. They have given people all autumn and winter to position themselves, now it's just a matter of being patient.·2 päivää sitten · MuokattuThanks. Completely agree that the autumn was used by management to position Curasight and after a period of intensive news flow, Curasight has now entered a phase where silence in itself is information. It is precisely in this transition – from public validation to Big Pharma's internal decision-making maturation – that many investors experience uncertainty, because there are no longer frequent data points or other communication from the company. But where is Curasight really in the process, what does the capital preparedness mean and how should the communication be interpreted – what does the current silence actually signal – both to the market and to Big Pharma. --------------------------------------------------------- 1. Capital Preparedness – Fenja in correct context The Fenja loan agreement (potential dilution of approx. 2 million shares) should not be read as a sign of weakness, but as deliberate bridge financing. The agreement: • secures runway until expected milestone payments from Curium • eliminates short-term capital stress • strengthens Curasight's negotiating position A dilution of approx. 4–5 % is a low price for strategic freedom. For industrial players, the signal is clear: Curasight is not a forced seller. And a company without capital stress can afford to say no – and wait. ------------------------------------------------------- 2. What is Big Pharma doing now? Big Pharma is not passively awaiting. Under NDA, typically occurs: • ongoing receipt of updated clinical data • internal investment and portfolio discussions • ongoing updating of price and risk models • structure and timing considerations (option vs. acquisition) • competitor monitoring: “are there others in the room?” Waiting time is used for risk reduction and decision maturation – not stagnation. ---------------------------------------------------------- 3. Communication, silence and FBM Curasight is not obliged to communicate: • NDA dialogues • ongoing negotiations • potential strategic interest An FBM is only issued when a binding agreement exists. The classic sequence is: NDA → data sharing → terms → board approval → FBM Silence in this phase is therefore not an absence of activity, but standard and value-preserving practice. ----------------------------------------------------------- 4. Preparatory communication is key. The current communication is process-oriented, low-key, and legally balanced. It signals readiness without locking in structure, timing, or price. Preparatory communication is typically only used when: • the mechanistic risk is reduced • capital pressure is low • several strategic structures are possible • timing is strategically important This precisely matches Curasight's situation. ----------------------------------------------------------- Conclusion: The Curasight case is not finished – but it is finished being early. The case is now in a decision space where timing, structure, and competition mean more than the mechanism itself. This is mentally demanding, because it is precisely here that the greatest asymmetries arise – but analytically, the picture is consistent. In principle, the market could wake up to an FBM where: • the company has been sold to a Big Pharma company • or where an optioned partnership agreement has been entered into for the coming months in connection with further clinical development of uTREAT Both will in practice make the case more expensive for Big Pharma, because further clinical progress further reduces the risk. Everything currently points in a constructive direction. This does not change the fact that discipline is required – but at present, there is nothing that indicates structural weakness.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
250
Myynti
Määrä
5 860
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 250 | AVA | NON | ||
| 500 | NON | NON | ||
| 640 | NON | NON | ||
| 782 | NON | NON | ||
| 224 | AVA | NON |
Ylin
12,65VWAP
Alin
11,85VaihtoMäärä
1 80 131
VWAP
Ylin
12,65Alin
11,85VaihtoMäärä
1 80 131
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
2025 Q3 -tulosraportti
59 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sitten · MuokattuTechnical Analysis Curasight is in a rising trend channel in the medium term. Rising trends indicate that the company is in a positive development, and that buying interest among investors is increasing. There is no resistance in the price chart, and a further upturn is indicated. In case of reactions back, the stock has support at approximately 6.40 kronor. https://www.investtech.com/dk/market.php?CompanyID=46110272
- ·1 päivä sittenYet another site where Curasight's name has popped up. Published 4 hours ago: https://www.towardshealthcare.com/companies/brain-cancer-companies Towardshealthcare describes themselves as: "We are a global strategy consulting firm based in Canada and India, dedicated to helping business leaders gain a competitive edge and accelerate growth. As a trusted provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, we are committed to building creative partnerships that generate actionable insights and drive meaningful innovation."
- ·1 päivä sittenSales order for 51,022 units at 12.60 kr 🥲
- ·1 päivä sittenCurasight is mentioned in this LinkedIn post: Radioimmunotherapy Market Overview: Significant Growth Potential with 14.5% CAGR Forecast from 2026 to 2033 https://www.linkedin.com/pulse/radioimmunotherapy-market-overview-significant-growth-potential-q0jhf?utm_source=share&utm_medium=member_android&utm_campaign=share_via
- ·2 päivää sittenThanks for the input, SweetSpot. Good observations. I agree that silence should probably be expected - but for once, it can advantageously be regarded as positive silence. Conversely, I would become skeptical if a company were to adorn itself with a lot of feathers right now; then one would almost instinctively know that JPM had not been a success. Silence right now must, all things considered, mean that one is quietly working through the current processes and everything is proceeding calmly in the background. No reason to shout out loud unless something "must" be announced. They have given people all autumn and winter to position themselves, now it's just a matter of being patient.·2 päivää sitten · MuokattuThanks. Completely agree that the autumn was used by management to position Curasight and after a period of intensive news flow, Curasight has now entered a phase where silence in itself is information. It is precisely in this transition – from public validation to Big Pharma's internal decision-making maturation – that many investors experience uncertainty, because there are no longer frequent data points or other communication from the company. But where is Curasight really in the process, what does the capital preparedness mean and how should the communication be interpreted – what does the current silence actually signal – both to the market and to Big Pharma. --------------------------------------------------------- 1. Capital Preparedness – Fenja in correct context The Fenja loan agreement (potential dilution of approx. 2 million shares) should not be read as a sign of weakness, but as deliberate bridge financing. The agreement: • secures runway until expected milestone payments from Curium • eliminates short-term capital stress • strengthens Curasight's negotiating position A dilution of approx. 4–5 % is a low price for strategic freedom. For industrial players, the signal is clear: Curasight is not a forced seller. And a company without capital stress can afford to say no – and wait. ------------------------------------------------------- 2. What is Big Pharma doing now? Big Pharma is not passively awaiting. Under NDA, typically occurs: • ongoing receipt of updated clinical data • internal investment and portfolio discussions • ongoing updating of price and risk models • structure and timing considerations (option vs. acquisition) • competitor monitoring: “are there others in the room?” Waiting time is used for risk reduction and decision maturation – not stagnation. ---------------------------------------------------------- 3. Communication, silence and FBM Curasight is not obliged to communicate: • NDA dialogues • ongoing negotiations • potential strategic interest An FBM is only issued when a binding agreement exists. The classic sequence is: NDA → data sharing → terms → board approval → FBM Silence in this phase is therefore not an absence of activity, but standard and value-preserving practice. ----------------------------------------------------------- 4. Preparatory communication is key. The current communication is process-oriented, low-key, and legally balanced. It signals readiness without locking in structure, timing, or price. Preparatory communication is typically only used when: • the mechanistic risk is reduced • capital pressure is low • several strategic structures are possible • timing is strategically important This precisely matches Curasight's situation. ----------------------------------------------------------- Conclusion: The Curasight case is not finished – but it is finished being early. The case is now in a decision space where timing, structure, and competition mean more than the mechanism itself. This is mentally demanding, because it is precisely here that the greatest asymmetries arise – but analytically, the picture is consistent. In principle, the market could wake up to an FBM where: • the company has been sold to a Big Pharma company • or where an optioned partnership agreement has been entered into for the coming months in connection with further clinical development of uTREAT Both will in practice make the case more expensive for Big Pharma, because further clinical progress further reduces the risk. Everything currently points in a constructive direction. This does not change the fact that discipline is required – but at present, there is nothing that indicates structural weakness.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
250
Myynti
Määrä
5 860
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 250 | AVA | NON | ||
| 500 | NON | NON | ||
| 640 | NON | NON | ||
| 782 | NON | NON | ||
| 224 | AVA | NON |
Ylin
12,65VWAP
Alin
11,85VaihtoMäärä
1 80 131
VWAP
Ylin
12,65Alin
11,85VaihtoMäärä
1 80 131
Välittäjätilasto
Dataa ei löytynyt